A
Alain Soupart
Researcher at Erasmus University Rotterdam
Publications - 66
Citations - 3377
Alain Soupart is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Hyponatremia & Uric acid. The author has an hindex of 25, co-authored 63 publications receiving 3072 citations. Previous affiliations of Alain Soupart include Université libre de Bruxelles & Free University of Brussels.
Papers
More filters
Journal ArticleDOI
Clinical practice guideline on diagnosis and treatment of hyponatraemia
Goce Spasovski,Raymond Vanholder,Bruno Allolio,Djillali Annane,Steve S. Ball,Daniel G. Bichet,Guy Decaux,Wiebke W. Fenske,Ewout J. Hoorn,Carole Ichai,Michael Joannidis,Alain Soupart,Robert Zietse,Maria M. Haller,Sabine S. Van Der Veer,Wim Van Biesen,E Nagler +16 more
TL;DR: The Clinical Practice Guideline on the diagnostic approach and treatment of hyponatraemia is developed as a joint venture of three societies representing specialists with a natural interest in hyponatonemia to obtain a common and holistic view.
Journal ArticleDOI
Non-peptide arginine-vasopressin antagonists: the vaptans
TL;DR: The vaptans are orally and intravenously active non-peptide vasopressin receptor antagonists that are in development and have shown initial positive results in the treatment of Raynaud's disease, dysmenorrhoea, and tocolysis.
Journal Article
Therapeutic recommendations for management of severe hyponatremia: current concepts on pathogenesis and prevention of neurologic complications.
Alain Soupart,Guy Decaux +1 more
TL;DR: Patients with hyponatremia are exposed to major neurological complications which potentially leads to subsequent neuropathological sequelae or death, and understanding of brain adaptative mechanisms to changes in osmolality largely contributes to explain these neurological events.
Journal ArticleDOI
Successful Long-Term Treatment of Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion with Satavaptan (SR121463B), an Orally Active Nonpeptide Vasopressin V2-Receptor Antagonist
Alain Soupart,Peter Gross,Jean-Jacques Legros,Sándor Alföldi,Djillali Annane,Hassan M. Heshmati,Guy Decaux +6 more
TL;DR: The new oral vasopressin V(2)-receptor antagonist satavaptan adequately corrects mild or moderate hyponatremia in patients with SIADH and has a good safety profile.
Journal ArticleDOI
Efficacy and Tolerance of Urea Compared with Vaptans for Long-Term Treatment of Patients with SIADH
TL;DR: Urea has efficacy similar to that of vaptans for treatment of chronic SIADH, and tolerance is generally good for both agents.